

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Incorporation of (α -*P*-Borano)-2',3'-dideoxycytidine 5'-Triphosphate into DNA by Drug-Resistant MMLV Reverse Transcriptase and *Taq* DNA Polymerase

Mikhail I. Dobrikov^a; Zinaida A. Sergueeva^a; Barbara Ramsay Shaw^{ab}

^a Department of Chemistry, P.M. Gross Chemical Laboratory, Duke University, Durham, North Carolina, USA ^b Department of Chemistry, P.M. Gross Chemical Laboratory, Duke University, Durham, NC, USA

Online publication date: 09 August 2003

To cite this Article Dobrikov, Mikhail I. , Sergueeva, Zinaida A. and Shaw, Barbara Ramsay(2003) 'Incorporation of (α -*P*-Borano)-2',3'-dideoxycytidine 5'-Triphosphate into DNA by Drug-Resistant MMLV Reverse Transcriptase and *Taq* DNA Polymerase', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 1651 – 1655

To link to this Article: DOI: 10.1081/NCN-120023091

URL: <http://dx.doi.org/10.1081/NCN-120023091>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Incorporation of (α -*P*-Borano)-2',3'-dideoxycytidine 5'-Triphosphate into DNA by Drug-Resistant MMLV Reverse Transcriptase and *Taq* DNA Polymerase

Mikhail I. Dobrikov, Zinaida A. Sergueeva, and Barbara Ramsay Shaw*

Department of Chemistry, P.M. Gross Chemical Laboratory,
Duke University, Durham, North Carolina, USA

ABSTRACT


The *Rp*-stereoisomer of 5'-(α -*P*-borano)triphosphates of 2'-deoxycytidine (*Rp*-dCTP α B) and 2',3'-dideoxycytidine (*Rp*-ddCTP α B) were synthesized. Their steady-state kinetics of incorporation by ddNTP-resistant enzymes, e.g., MMLV reverse transcriptase (RT) and *Taq* DNA polymerase, were investigated and compared with incorporation of dCTP and ddCTP. The α -boranophosphate substitution in ddCTP results in a 28-fold increase in efficiency of incorporation of the *Rp*-ddCTP α B isomer by MMLV RT, yet has minimal effect on the efficiency of incorporation by *Taq* DNA polymerase.

Nucleoside boranophosphates^[1–5] comprise a new class of modified nucleotides in which one non-bridging oxygen atom in the α -phosphate of the nucleoside 5'-triphosphate is replaced by a borane group (BH₃). Our previous studies have shown that one stereo isomer (*Rp*-) of the 2'-deoxynucleoside 5'-(α -*P*-borano)triphosphate


*Correspondence: Barbara Ramsay Shaw, Department of Chemistry, P.M. Gross Chemical Laboratory, Duke University, Durham, NC 27708-0346, USA; Fax: +1 919 660 1618; E-mail: brshaw@chem.duke.edu.



sphates (*Rp*-dNTP α Bs)^[4] and the 5-methyl-, ethyl-, bromo-, and iodo-*Rp*-dCTP α Bs^[5] can be successfully incorporated into DNA by DNA polymerases. Moreover, *Rp*-(α -*P*-borano)triphosphates of the clinically relevant antiviral drugs AZT, d4T^[6,7] and ddA^[8] were shown to be better substrates for wild-type and mutant drug-resistant forms of HIV-1 reverse transcriptase (RT) than nonboronated chain terminators. To obtain insight into the structural basis for discrimination of ddNTPs over dNTPs by viral and bacterial DNA polymerases, we synthesized the *Rp*-stereoisomer of 5'-(α -*P*-borano)triphosphates of 2'-deoxycytidine (*Rp*-dCTP α B, **2**) and 2',3'-dideoxycytidine (*Rp*-ddCTP α B, **4**). Steady-state kinetics of incorporation of dCTP (**1**), dCTP (**3**), *Rp*-dCTP α B (**2**) and *Rp*-ddCTP α B (**4**) by the ddNTP-resistant enzymes, MMLV RT and *Taq* DNA polymerase, were investigated.



Synthesis of *Rp*-(α -*P*-borano)-2',3'-dideoxycytidine 5'-triphosphate (4**).** Dideoxycytidine (ddC, **5**) (0.5 mmol) dried over P₂O₅ under vacuum and suspended in 0.8 mL of anhydrous DMF and 0.2 mL pyridine was phosphitylated with 2-chloro-4*H*-1,3,2-benzodioxaphosphorin-4-one (0.55 mmol in 0.8 anhydrous DMF)



Scheme 1.

at 0°C for 15 min to yield two diastereomers of 2',3-dideoxycytidine 5'-(4*H*-1,3,2-benzodioxaphosphorin-4-one) **6** (Sch. 1). They were identified by the appearance of a doublet around 127 ppm in the ^{31}P NMR spectra. Compound **6** was treated with tributylammonium pyrophosphate (240 mg in 1 mL anhydrous DMF and 0.15 mL triethylamine) at rt for 1 h to form a 2',3'-dideoxycytidine 5'- P^2,P^3 -dioxo- P^1 -cyclo-triphosphate **7**. The upfield shift from ~ 127 to 107 ppm for trivalent α -phosphorus P^{III} , together with a doublet at -18 ppm for pentavalent phosphorus P^{V} in ^{31}P NMR, confirmed the complete formation of compound **7**. The borano group was




Figure 1. Double reciprocal plot for determination of the steady-state kinetic constants of incorporation of dCTP analogues by *Taq* DNA polymerase (A) and MMLV RT (B). Solutions of 22/27 T1-template/primer (350 μM) with increasing concentrations of dCTP (\blacktriangle), *Rp*-dCTP α B (\square'), ddCTP (\triangle) or *Rp*-ddCTP α B (\blacksquare) were preincubated at 60°C (A) or 37°C (B) and mixed with 0.5 nM *Taq* polymerase (A) or 1 nM MMLV RT (B) to start the reactions. After 1 min incubation the reactions were quenched. The products were separated by 12%-PAGE and quantified by laser fluorescent imaging. To determine K_m and k_{cat} values, the inverse values of velocity were plotted against inverse substrate concentration. The straight lines intercept the vertical axis at $1/V_{\text{max}}$ value and the horizontal axis at $-1/K_m$. The determined kinetic constants are presented in Table 1.



Table 1. Steady-state kinetic constants of incorporation of dCTP analogues.

Enzyme	Substrate	K_m (μM) ^a	k_{cat} (sec^{-1}) ^a	k_{cat}/K_m ($\text{s}^{-1}\text{nM}^{-1}$)	S^b
MMLV RT	dCTP	7.2 ± 1.3	0.086 ± 0.012	12	1
	<i>Rp</i> -dCTP α B	14.8 ± 4.1	0.080 ± 0.025	5.4	2.2
	ddCTP	93 ± 23	0.014 ± 0.005	0.15	80
	<i>Rp</i> -ddCTP α B	14.6 ± 2.8	0.060 ± 0.018	4.1	2.9
<i>Taq</i> DNA polymerase	dCTP	7.1 ± 1.3	0.16 ± 0.06	23	1
	<i>Rp</i> -dCTP α B	11.5 ± 1.7	0.031 ± 0.011	2.7	8.5
	ddCTP	42.6 ± 7.2	0.0007 ± 0.0001	0.017	1360
	<i>Rp</i> -ddCTP α B	36.2 ± 6.7	0.0005 ± 0.0001	0.015	1530

^aThe kinetic constants were determined from double-reciprocal plots of $1/v$ vs. $1/[\text{dNTP}]$. Each value is the average of at least six separate experiments and is reported as mean \pm SD.

^bThe selectivity for dCTP over its modified analogues is given by the ratio of the efficiencies (k_{cat}/K_m) of incorporation of dCTP to its analogues. The value greater than 1 means that the enzyme discriminates the analog over the dCTP.

introduced by the reaction of derivative **7** with excess borane-diisopropylethylamine complex (4.7 mmol) at rt for 16 h to produce N³-borano-2',3'-dideoxycytidine 5'-(α -*P*-borano)cyclotriphosphate **8**. Cyclotriphosphate **8** was converted to N³-borano-2',3'-dideoxycytidine 5'-(α -*P*-borano)triphosphate **9** by treatment with H₂O at rt overnight and then to triphosphate **4** by treatment with NH₃/H₂O:CH₃OH = 1:1, (v/v) at rt for 8 h. After extraction with Et₂O the water layer was evaporated. For ion-exchange chromatography, the resulting crude mixture was applied to a Polysil-CA column and eluted with a linear gradient of 0–0.3 M KH₂PO₄ (pH = 6.5) in 30% CH₃CN. Appropriate fractions were collected and evaporated to give triphosphate **4** as the ammonium salt. The desired fractions were lyophilized, and the excess salt was removed by repeated lyophilization with deionized water for 46% yield of the triethylammonium salt of triphosphate **4**. The stereoisomers were separated on a Delta-Pak C18 cartridge (25 \times 40 mm) in isocratic conditions: 2.5% CH₃CN in 0.02 M TEAB at pH 8.0. NMR spectra were recorded on a Varian Inova-400 spectrometer operating at 121.4 Hz (³¹P) or 400 Hz (¹H). Chemical shift values (δ) are reported relative to H₃PO₄ (85%) for ³¹P NMR (external standard), *Rp*-isomer of triphosphate **4**: ¹H NMR (D₂O), δ (ppm): 7.96 (d, 1H, H-6), 5.92 (m, 2H, H-5 + H-1'), 4.21 (m, 1H, H-4'), 4.1 (m, 1H, H-5'), 4.02 (m, 1H, H-5''), 2.86 (m, 1H, H-3'), 2.26 (m, 1H, H-3''), 1.91 (m, 2H, H-2' + 2''), 0.4–0.1 (br, 3H, BH₃); ³¹P NMR (D₂O), δ (ppm): 82 (br, 1P, α -P), –8.9 (m, 1P, γ -P), –21.89 (m, 1P, β -P). UV (H₂O), λ_{max} , nm, (ϵ , M^{–1}cm^{–1}): 272 (9.1).

Steady-State Kinetic Analysis. Steady-state kinetics of incorporation of dCTP, ddCTP, *Rp*-dCTP α B, and *Rp*-ddCTP α B by the ddNTP-resistant enzymes, MMLV RT and *Taq* DNA polymerase, were investigated. Steady-state assays (Fig. 1) showed that relative to dCTP, the efficiencies of incorporation of ddCTP, *Rp*-dCTP α B, and *Rp*-ddCTP α B isomers were 80-, 2.2-, and 2.9-fold less for MMLV RT, respectively, but 1360-, 8.5-, and 1530-fold less for *Taq* polymerase, respectively (Table 1).

The α -boranophosphate substitution in ddCTP results in a 28-fold increase in efficiency of incorporation of the *Rp*-ddCTP α B isomer by MMLV RT, whereas it slightly decreases the efficiency of incorporation by *Taq* DNA polymerase.

ACKNOWLEDGMENT

This work was supported by the NIH grant R01 AI52061 to B.R.S.

REFERENCES

1. Tomasz, J.; Shaw, B.R.; Porter, K.; Spielvogel, B.F.; Sood, A. *Angew. Chem. (Engl. Ed.)* **1992**, *31*, 1373–1375.
2. Krzyzanowska, B.K.; He, K.; Hasan, A.; Shaw, B.R. *Tetrahedron* **1998**, *54*, 5119–5128.
3. He, K.; Hasan, A.; Krzyzanowska, B.K.; Shaw, B.R. *J. Org. Chem.* **1998**, *63*, 5769–5773.
4. Li, H.; Porter, K.; Huang, F.; Shaw, B.R. *Nucleic Acid Res.* **1995**, *21*, 4495–4501.
5. He, K.; Porter, K.W.; Hasan, A.; Briley, J.D.; Shaw, B.R. *Nucleic Acid Res.* **1999**, *37*, 1788–1794.
6. Schneider, B.; Meyer, P.; Sarfati, S.; Mulard, L.; Guerreiro, C.; Boretto, J.; Janin, J.; Veron, M.; Deville-Bonne, D.; Canard, B. *Nucleoside Nucleotide Nucl. Acids* **2001**, *20*, 297–306.
7. Meyer, P.; Schneider, B.; Sarfati, S.; Deville-Bonne, D.; Guerreiro, C.; Boretto, J.; Janin, J.; Veron, M.; Canard, B. *EMBO J.* **2000**, *19*, 3520–3529.
8. Selmi, B.; Boretto, J.; Sarfati, S.R.; Guerreiro, C.; Canard, B. *J. Biol. Chem.* **2001**.



